Zydus has received final approval from the USFDA for Glatiramer Acetate Injection, 20 mg/mL and 40 mg/mL, single-dose prefilled syringes.

The intervention consists of 30 weeks of treatment with once-weekly subcutaneous injections of either semaglutide (1.34 mg/mL; 1.0 mg) or placebo. The current dose adjustment guidelines for ...

Once-weekly combination therapy of basal insulin icodec and semaglutide was noninferior to insulin glargine plus insulin aspart for lowering HbA1c among adults with type 2 diabetes, according to ...

The product, a once-weekly glucagon-like peptide-1 (GLP-1) analog, will be available as a 1.34-mg/mL injectable solution.